Ignyta Company Profile (NASDAQ:RXDX)

About Ignyta (NASDAQ:RXDX)

Ignyta logoIgnyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RXDX
  • CUSIP: N/A
  • Web: www.ignyta.com
Capitalization:
  • Market Cap: $888.8 million
  • Outstanding Shares: 56,253,000
Average Prices:
  • 50 Day Moving Avg: $12.70
  • 200 Day Moving Avg: $9.75
  • 52 Week Range: $4.15 - $18.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.68
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.04 per share
  • Price / Book: 7.75
Profitability:
  • EBITDA: ($114,260,000.00)
  • Return on Equity: -123.52%
  • Return on Assets: -75.75%
Debt:
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 7.30%
  • Quick Ratio: 7.31%
Misc:
  • Average Volume: 1.18 million shs.
  • Beta: 2.03
  • Short Ratio: 4.57
 

Frequently Asked Questions for Ignyta (NASDAQ:RXDX)

What is Ignyta's stock symbol?

Ignyta trades on the NASDAQ under the ticker symbol "RXDX."

How were Ignyta's earnings last quarter?

Ignyta, Inc. (NASDAQ:RXDX) issued its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.63) by $0.07. View Ignyta's Earnings History.

Where is Ignyta's stock going? Where will Ignyta's stock price be in 2017?

3 brokers have issued 1 year target prices for Ignyta's stock. Their forecasts range from $15.00 to $31.00. On average, they expect Ignyta's stock price to reach $23.25 in the next twelve months. View Analyst Ratings for Ignyta.

What are analysts saying about Ignyta stock?

Here are some recent quotes from research analysts about Ignyta stock:

  • 1. According to Zacks Investment Research, "Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. " (10/18/2017)
  • 2. Cantor Fitzgerald analysts commented, "Entrectinib has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), for NTRK fusion-positive solid tumors, primarily based on STARTRK-2 results." (10/17/2017)
  • 3. Jefferies Group LLC analysts commented, "ENA preclinical posters on RXDX-106 showed encouraging activity in both immuno-oncologic modulation and direct tumor targeting. These initial data support further development of ‘106 and we would look for more details at Dec 1 conference call. Incremental preclinical data of ‘105 and entrectinib were also presented." (11/30/2016)

Who are some of Ignyta's key competitors?

Who are Ignyta's key executives?

Ignyta's management team includes the folowing people:

  • Jonathan E. Lim M.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder
  • Jacob M. Chacko M.D., Chief Financial Officer
  • Zachary Hornby, Chief Operating Officer
  • Valerie Harding Start Ph.D., Senior Vice President - Chemistry, Manufacturing, and Controls
  • Christian V. Kuhlen M.D. Esq., General Counsel, Secretary
  • William R. McCarthy, Chief Business Officer
  • Pratik S. Multani M.D., Chief Medical Officer
  • James A. Bristol Ph.D., Independent Director
  • Alexander W. Casdin, Independent Director
  • Heinrich Dreismann Ph.D., Independent Director

How do I buy Ignyta stock?

Shares of Ignyta can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ignyta's stock price today?

One share of Ignyta stock can currently be purchased for approximately $15.80.


MarketBeat Community Rating for Ignyta (NASDAQ RXDX)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about Ignyta and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ignyta (NASDAQ:RXDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.25 (47.15% upside)
Consensus Price Target History for Ignyta (NASDAQ:RXDX)
Price Target History for Ignyta (NASDAQ:RXDX)
Analysts' Ratings History for Ignyta (NASDAQ:RXDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/18/2017Ladenburg Thalmann Financial ServicesBoost Price Target$20.25 -> $31.00N/AView Rating Details
10/17/2017Cantor FitzgeraldSet Price TargetBuy$15.00N/AView Rating Details
10/12/2017J P Morgan Chase & CoReiterated RatingBuy$18.00 -> $20.00N/AView Rating Details
6/22/2017Jefferies Group LLCReiterated RatingBuy -> Buy$27.00HighView Rating Details
8/10/2016Piper Jaffray CompaniesLower Price TargetOverweight$32.00 -> $20.00N/AView Rating Details
7/12/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
5/12/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Ignyta (NASDAQ:RXDX)
Earnings by Quarter for Ignyta (NASDAQ:RXDX)
Earnings History by Quarter for Ignyta (NASDAQ RXDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.63)($0.56)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.69)($0.96)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.67)($0.56)ViewN/AView Earnings Details
5/10/2016Q1($0.68)($0.79)ViewListenView Earnings Details
3/14/2016Q415($0.57)($1.32)ViewN/AView Earnings Details
11/9/2015Q315($0.60)($0.49)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.51)ViewListenView Earnings Details
5/11/2015Q115($0.79)($1.15)ViewListenView Earnings Details
4/14/2015($0.79)($1.05)ViewN/AView Earnings Details
3/17/2015Q414($0.59)($2.18)ViewN/AView Earnings Details
11/7/2014Q314$0.01($0.55)$215.50 millionViewN/AView Earnings Details
8/12/2014($0.26)($0.28)$0.15 millionViewN/AView Earnings Details
5/12/2014($0.37)($0.28)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ignyta (NASDAQ:RXDX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.69)($0.69)($0.69)
Q3 20171($0.53)($0.53)($0.53)
Q4 20171($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ignyta (NASDAQ:RXDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ignyta (NASDAQ:RXDX)
Insider Ownership Percentage: 13.08%
Institutional Ownership Percentage: 80.82%
Insider Trades by Quarter for Ignyta (NASDAQ:RXDX)
Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)
Insider Trades by Quarter for Ignyta (NASDAQ:RXDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016James A BristolDirectorBuy5,000$5.65$28,250.00View SEC Filing  
5/4/2016Alexander W CasdinDirectorBuy232,000$6.25$1,450,000.00View SEC Filing  
3/17/2016Jacob ChackoCFOBuy10,000$5.64$56,400.00View SEC Filing  
3/17/2016James L FreddoDirectorBuy3,000$5.39$16,170.00View SEC Filing  
3/17/2016Jonathan E LimCEOBuy24,852$5.51$136,934.52View SEC Filing  
12/16/2015Jacob ChackoCFOBuy1,500$12.00$18,000.00View SEC Filing  
8/20/2015City Hill Venture Partners I,major shareholderBuy8,480$12.90$109,392.00View SEC Filing  
6/15/2015Robert WildVPBuy1,200$16.35$19,620.00View SEC Filing  
3/20/2015Jonathan E LimCEOBuy20,000$9.01$180,200.00View SEC Filing  
3/17/2015Alexander W CasdinDirectorBuy408,750$10.00$4,087,500.00View SEC Filing  
11/24/2014Jacob ChackoCFOBuy1,598$6.46$10,323.08View SEC Filing  
8/19/2014Jacob ChackoCFOBuy1,840$7.53$13,855.20View SEC Filing  
8/15/2014Jonathan E LimCEOBuy5,000$7.60$38,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ignyta (NASDAQ:RXDX)
Latest Headlines for Ignyta (NASDAQ:RXDX)
Source:
Loading headlines, please wait.

Social

Chart

Ignyta (RXDX) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.